OSE Immunotherapeutics appoints Nicolas Poirier as Chief Executive Officer
12 October 2022OSE Immunotherapeutics is pleased to announce the appointment of Dr. Nicolas Poirier as new Chief Executive Officer. This appointment follows... View Article
Valneva raises more than 100 million euros
5 October 2022The financing was led by US healthcare specialist Deep Track Capital and also included existing shareholders such as French state-owned... View Article
The biotechnology company HEMARINA obtains the CE mark for its HEMO2life® technology
30 September 2022A major breakthrough innovation for organ transplants Thanks to the CE marking obtained for its additive to organ preservation solutions... View Article